Earnings results for Unity Biotechnology (NASDAQ:UBX)
Estimate Momentum measures change in analyst sentiment over time and may be an indicator of future price movements. The Change in Consensus chart shows the current, 1 week ago, and 1 month ago consensus earnings per share (EPS*) forecasts. For the fiscal quarter endingJun 2020 , the consensus EPS* forecast has remained the same over the past week at 999 and remained the same over the past month at 999. none raised and none lowered their forecast. For the fiscal year ending Dec 2020 , the consensus EPS* forecast has remained the same over the past week at -1.92 and remained the same over the past month at -1.92 . none raised and none lowered their forecast.
Unity Biotechnology last released its quarterly earnings data on May 7th, 2020. The reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $0.03. Unity Biotechnology has generated ($1.88) earnings per share over the last year. Unity Biotechnology has confirmed that its next quarterly earnings report will be published on Friday, July 31st, 2020.
Analyst Opinion on Unity Biotechnology (NASDAQ:UBX)
4 Wall Street analysts have issued ratings and price targets for Unity Biotechnology in the last 12 months. Their average twelve-month price target is $25.25, suggesting that the stock has a possible upside of 173.27%. The high price target for UBX is $35.00 and the low price target for UBX is $13.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Unity Biotechnology has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $25.25, Unity Biotechnology has a potential upside of 173.3% from its current price of $9.24. Unity Biotechnology has only been the subject of 1 research reports in the past 90 days.
Dividend Strength: Unity Biotechnology (NASDAQ:UBX)
Unity Biotechnology does not currently pay a dividend. Unity Biotechnology does not have a long track record of dividend growth.
Insiders buying/selling: Unity Biotechnology (NASDAQ:UBX)
In the past three months, Unity Biotechnology insiders have not sold or bought any company stock. Only 33.60% of the stock of Unity Biotechnology is held by insiders. 44.56% of the stock of Unity Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Unity Biotechnology (NASDAQ:UBX
Earnings for Unity Biotechnology are expected to grow in the coming year, from ($1.92) to ($1.87) per share. The P/E ratio of Unity Biotechnology is -4.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Unity Biotechnology is -4.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
More latest stories: here